New anti-inflammatory treatment strategy in Alzheimer's disease

Japanese Journal of Pharmacology

Volumn 82, Issue 2, 2000, Pages 85-94

  Sugaya, Kiminobu ^a   Uz, Tolga ^a   Kumar, Vinod ^a   Manev, Hari ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

5 Lipoxygenase; Cyclooxygenase; Dementia; Inflammation; Nonsteroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; IBUPROFEN; ICOSANOID; INDOMETACIN; INTERLEUKIN 6; LEUKOTRIENE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; MESSENGER RNA; MISOPROSTOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; STEROID; TEPOXALIN; TRANSCRIPTION FACTOR; UNINDEXED DRUG; ZILEUTON;

AGING; ALZHEIMER DISEASE; BRAIN DEGENERATION; CELL PROTECTION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; GASTRODUODENAL ULCER; GASTROINTESTINAL TRACT; GENE EXPRESSION; HUMAN; INFLAMMATORY DISEASE; RECEPTOR UPREGULATION; REVIEW; RISK MANAGEMENT; TISSUE INJURY;

EID: 0034101592     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.82.85     Document Type: Review

References (111)

1. McGeer PL, McGeer E, Rogers J and Sibley J: Anti-inflammatory drugs and Alzheimer disease. Lancet 335, 1037 (1990)
2. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 44, 2073-2080 (1994)
3. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ and Anthony JC: Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44, 227-232 (1994)
4. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA and Saunders AM: Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16, 523-530 (1995)
5. Breitner JC: The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 47, 401-411 (1996)
6. McGeer PL, Schulzer M and McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies [see comments]. Neurology 47, 425-432 (1996)
7. Sugaya K and McKinney M: Nitric oxide synthase gene expression in cholinergic neurons in the rat brain examined by combined immunocytochemistry and in situ hybridization histochemistry. Brain Res Mol Brain Res 23, 111-125 (1994)
8. Sugaya K, Chouinard M and McKinney M: Immunostimulation protects microglial cells from nitric oxide-mediated apoptosis. Neuroreport 8, 2241-2245 (1997)
9. Sugaya K, Chouinard ML and McKinney M: Induction of manganese superoxide dismutase in BV-2 microglial cells. Neuroreport 8, 3547-3551 (1997)
10. Balazs L and Leon M: Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 19, 1131-1137 (1994)
11. Furuta A, Price DL, Pardo CA, Troncoso JC, Xu Z-S, Taniguchi N and Martin LJ: Localization of superoxide dismutases in Alzheimer's diseae and Down's syndrome neocortex and hippocampus. Am J Pathol 146, 357-367 (1995)
12. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H and Riederer P: Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64, 1216-1223 (1995)
13. Martins RN, Harper CG, Stokes GB and Masters CL: Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 46, 1042-1045 (1986)
14. Pappolla MA, Omar RA, Kim KS and Robakis NK: Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 140, 621-628 (1992)
15. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA and Markesbery WR: Excess brain protein oxidization and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88, 10540-10543 (1993)
16. Bergstrom S, Danielsson H and Samuelsson B: The enzymic formation of prostaglandin E2 from arachidonic acid. Prostaglandins and related factors 32. Biochim Biophys Acta 90, 207-210 (1964)
17. Nogawa S, Zhang F, Ross ME and Iadecola C: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17, 2746-2755 (1997)
18. Yasojima K, Schwab C, McGeer EG and McGeer PL: Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830, 226-236 (1999)
19. Kitamura Y, Shimohama S, Koike H, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ and Taniguchi T: Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 254, 582-586 (1999)
20. Pasinetti GM and Aisen PS: Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87, 319-324 (1998)
21. Lukiw WJ and Bazan NG: Strong nuclear factor-κB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 53, 583-592 (1998)
22. D'Acquisto F, Iuvone T, Rombola L, Sautebin L, Di Rosa M and Carnuccio R: Involvement of NF-κB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett 418, 175-178 (1997)
23. Prasad KN, La Rosa FG and Prasad JE: Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and beta-amyloid. In Vitro Cell Dev Biol Anim 34, 265-274 (1998)
24. Fiebich BL, Hull M, Lieb K, Gyufko K, Berger M and Bauer J: Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J Neurochem 68, 704-709 (1997)
25. Fiebich BL, Hull M, Lieb K, Schumann G, Berger M and Bauer J: Potential link between interleukin-6 and arachidonic acid metabolism in Alzheimer's disease [In Process Citation]. J Neural Transm Suppl 54, 268-278 (1998)
26. Licastro F, Davis LJ, Pedrini S, Galasko D and Masliah E: Prostaglandin E2 induced polymerization of human alpha-1-antichymotrypsin and suppressed its protease inhibitory activity: implications for Alzheimer's disease. Biochem Biophys Res Commun 249, 182-186 (1998)
27. Dash PK and Moore AN: Enhanced processing of APP induced by IL-1 beta can be reduced by indomethacin and nordihydroguaiaretic acid. Biochem Biophys Res Commun 208, 542-548 (1995)
28. Lammers CH, Schweitzer P, Facchinetti P, Arrang JM, Madamba SG, Siggins GR and Piomelli D: Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J Neurochem 66, 147-152 (1996)
29. Manev H and Uz T: Primary cultures of rat cerebellar granule cells as a model to study neuronal 5-lipoxygenase and FLAP gene expression. Ann NY Acad Sci (1999) (in press)
30. Steinhilber D, Brungs M, Werz O, Wiesenberg I, Danielsson C, Kahlen JP, Nayeri S, Schrader M and Carlberg C: The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 270, 7037-7040 (1995)
31. Uz T, Dwivedi Y, Savani PD, Impagnatiello F, Pandey G and Manev H: Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain. J Neurochem 73, 693-699 (1999)
32. Uz T, Longone P and Manev H: Increased hippocampal 5-lipoxygenase mRNA content in melatonin-deficient, pinealectomized rats. J Neurochem 69, 2220-2223 (1997)
33. Uz T, Pesold C, Longone P and Manev H: Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J 12, 439-449 (1998)
34. Chakraborti T, Mandal M, Das S and Chakraborti S: Age-dependent change in arachidonic acid metabolic capacity in rat alveolar macrophages. Biochem Mol Biol Int 47, 501-507 (1999)
35. Shohami E, Glantz L, Nates J and Feuerstein G: The mixed lipoxygenase/cyclooxygenase inhibitor SK&F 105809 reduces cerebral edema after closed head injury in rat. J Basic Clin Physiol Pharmacol 3, 99-107 (1992)
36. Uz T and Manev H: Circadian expression of pineal 5-lipoxygenase mRNA. Neuroreport 9, 783-786 (1998)
37. Shirazi Y, Imagawa DK and Shin ML: Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J Neurochem 48, 271-278 (1987)
38. Hartung HP, Heininger K and Toyka KV: Primary rat astroglial cultures can generate leukotriene B4. J Neuroimmunol 19, 237-243 (1988)
39. Manev H: 5-Lipoxygenase gene promoter polymorphism and onset of Alzheimer's disease. Med Hypotheses (in press)
40. Alvarez XA, Franco A, Fernandez-Novoa L and Cacabelos R: Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 29, 237-252 (1996)
41. Cacabelos R, Alvarez XA, Fernandez-Novoa L, Franco A, Mangues R, Pellicer A and Nishimura T: Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol 16, 141-151 (1994)
42. Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B and Wolf-Klein G: Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 129, 318-320 (1991)
43. Hull M, Strauss S, Berger M, Volk B and Bauer J: The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav Brain Res 78, 37-41 (1996)
44. Grilli M, Goffi F, Memo M and Spano P: Interleukin-1β and glutamate activate the NF-κB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem 271, 15002-15007 (1996)
45. Lieb K, Fiebich BL, Schaller H, Berger M and Bauer J: Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-κB. J Neurochem 67, 2039-2044 (1996)
46. McDonald PP, Bald A and Cassatella MA: Activation of the NF-κB pathway by inflammatory stimuli in human neutrophils. Blood 89, 3421-3433 (1997)
47. Lieberman J, Schleissner L, Tachiki KH and Kling AS: Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 16, 747-753 (1995)
48. Van Gool D, De Strooper B, Van Leuven F, Triau E and Dom R: Alpha 2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease. Neurobiol Aging 14, 233-237 (1993)
49. Conti P, Panara MR, Barbacane RC, Placido FC, Bongrazio M, Reale M, Dempsey RA and Fiore S: Blocking the interleukin-1 receptor inhibits leukotriene B4 and prostaglandin E2 generation in human monocyte cultures. Cell Immunol 145, 199-209 (1992)
50. Palmantier R, Surette ME, Sanchez A, Braquet P and Borgeat P: Priming for the synthesis of 5-lipoxygenase products in human blood ex vivo by human granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. Lab Invest 70, 696-704 (1994)
51. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK and Lee W: Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 226, 810-818 (1996)
52. Martin M, Neumann D, Hoff T, Resch K, DeWitt DL and Goppelt-Struebe M: Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 45, 150-158 (1994)
53. Niiro H, Otsuka T, Ogami E, Yamaoka K, Nagano S, Akahoshi M, Nakashima H, Arinobu Y, Izuhara K and Niho Y: MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun 250, 200-205 (1998)
54. Porreca E, Reale M, Febbo CD, Gioacchino MD, Barbacane RC, Castellani ML, Baccante G, Conti P and Cuccurullo F: Down-regulation of cyclooxygenase-2 (COX-2) by interleukin-1 receptor antagonist in human monocytes. Immunology 89, 424-429 (1996)
55. Sugaya K, Chouinard M, Greene R, Robbins M, Personett D, Kent C, Gallagher M and McKinney M: Molecular indices of neuronal and glial plasticity in the hippocampal formation in a rodent model of age-induced spatial learning impairment. J Neurosci 16, 3427-3443 (1996)
56. Sugaya K, Greene R, Personett D, Robbins M, Kent C, Bryan D, Skiba E, Gallagher M and McKinney M: Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline. Neurobiol Aging 19, 351-361 (1998)
57. Akama KT, Albanese C, Pestell RG and Van Eldik LJ: Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism. Proc Natl Acad Sci USA 95, 5795-5800 (1998)
58. Hu J, Akama KT, Krafft GA, Chromy BA and Van Eldik LJ: Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 785, 195-206 (1998)
59. Landolfi C, Soldo L, Polenzani L, Apicella C, Capezzone de Joannon A, Coletta I, Di Cesare F, Brufani M, Pinza M and Milanese C: Inflammatory molecule release by beta-amyloid-treated T98G astrocytoma cells: role of prostaglandins and modulation by paracetamol [In Process Citation]. Eur J Pharmacol 360, 55-64 (1998)
60. Barger SW and Harmon AD: Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881 (1997)
61. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K and Cole GM: Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152, 307-317 (1998)
62. Netland EE, Newton JL, Majocha RE and Tate BA: Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging 19, 201 -204 (1998)
63. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E and Paul SM: The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 57, 63-72 (1998)
64. Du Yan S, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D and Schmidt AM: Amyloid-beta peptide-receptor for advanced glycation end-product interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 94, 5296-5301 (1997)
65. Fagarasan MO and Aisen PS: IL-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in PC12 cells. Brain Res 723, 231-234 (1996)
66. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D and Seubert P: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999)
67. Sugaya K, Reeves M and McKinney M: Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus. Neurochem Int 31, 275-281 (1997)
68. Chen S, Frederickson RC and Brunden KR: Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. Neurobiol Aging 17, 781-787 (1996)
69. Cribbs DH, Velazquez P, Soreghan B, Glabe CG and Tenner AJ: Complement activation by cross-linked truncated and chimeric full-length beta-amyloid. Neuroreport 8, 3457-3462 (1997)
70. Velazquez P, Cribbs DH, Poulos TL and Tenner AJ: Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat Med 3, 77-79 (1997)
71. Verbeek MM, Otte-Holler I, Veerhuis R, Ruiter DJ and De Waal RM: Distribution of Aβ-associated proteins in cerebrovascular amyloid of Alzheimer's disease [In Process Citation]. Acta Neuropathol (Berl) 96, 628-636 (1998)
72. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR and Rogers J: Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18, 415-421 (1997)
73. Barnum SR: Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 6, 132-146 (1995)
74. Korotzer AR, Watt J, Cribbs D, Tenner AJ, Burdick D, Glabe C and Cotman CW: Cultured rat microglia express Clq and receptor for Clq: implications for amyloid effects on microglia. Exp Neurol 134, 214-221 (1995)
75. Tooyama I, Kimura H, Akiyama H and McGeer PL: Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. Brain Res 523, 273-280 (1990)
76. Thomas W: Brain macrophages: evaluation of microglia and their functions. Brain Res Rev 17, 61-74 (1992)
77. Gordon MN: Microglia and immune activation in Alzheimer's disease. J Fla Med Assoc 80, 267-270 (1993)
78. McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I and McGeer EG: Microglia in degenerative neurological disease. Glia 7, 84-92 (1993)
79. Sugaya K, Jerome S, Bryan D, McKinney M, Duff K and Kumar V: Double transgenic mice carrying mutant amyloid β precursor protein and presenilin 1 genes express accelerated Alzheimer-like phenotype. the 28th Annu Meeting Soc Neurosci 285, 4 (1999)
80. Personett DA, Chouinard M, Sugaya K and McKinney M: Simplified RT/PCR quantitation of gene transcripts in cultured neuroblastoma (SN49) and microglial (BV-2) cells using capillary electrophoresis and laser-induced fluorescence. J Neurosci Methods 65, 77-91 (1996)
81. Sugaya K, Chou S, Xu SJ and McKinney M: Indicators of glial activation and brain oxidative stress after intraventricular infusion of endotoxin. Brain Res Mol Brain Res 58, 1-9 (1998)
82. Fiebich BL, Hull M, Lieb K, Schumann G, Berger M and Bauer J: Potential link between interleukin-6 and arachidonic acid metabolism in Alzheimer's disease [In Process Citation]. J Neural Transm Suppl 54, 268-278 (1998)
83. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW and Mrak RE: Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 8, 65-72 (1998)
84. Beard CM, Waring SC, O'Brien PC, Kurland LT and Kokmen E: Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 73, 951-955 (1998)
85. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C and Brandt J: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease [see comments]. Neurology 45, 51-55 (1995)
86. in 't Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM and Stricker BH: NSAIDs and incident Alzheimer's disease. The Rotterdam Study [see comments]. Neurobiol Aging 19, 607-611 (1998)
87. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS and Pasinetti GM: Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 57, 295-303 (1999)
88. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P and Kogan F: Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611 (1993)
89. Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T and Davis KL: A pilot study of prednisone in Alzheimer's disease. Dementia 7, 201-206 (1996)
90. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM and Hofman A: Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45, 1441-1445 (1995)
91. Mackenzie IR and Munoz DG: Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50, 986-990 (1998)
92. Silverstein FE: Improving the gastrointestinal safety of NSAIDs: the development of misoprostol - from hypothesis to clinical practice. Dig Dis Sci 43, 447-458 (1998)
93. Wallace JL: Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol Sci 20, 4-6 (1999)
94. Vane JR and Botting RM: Mechanism of action of antiinflammatory drugs. Int J Tissue React 20, 3-15 (1998)
95. Jouzeau JY, Terlain B, Abid A, Nedelec E and Netter P: Cyclooxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53, 563-582 (1997)
96. Gilroy DW, Tomlinson A and Willoughby DA: Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation [In Process Citation]. Eur J Pharmacol 355, 211-217 (1998)
97. Boado RJ, Pardridge WM, Vinters HV and Black KL: Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proc Natl Acad Sci USA 89, 9044-9048 (1992)
98. Ohtsuki T, Matsumoto M, Hayashi Y, Yamamoto K, Kitagawa K, Ogawa S, Yamamoto S and Kamada T: Reperfusion induces 5-lipoxygenase translocation and leukotriene C4 production in ischemic brain. Am J Physiol 268, H1249-H1257 (1995)
99. Winking M, Heldt RM and Simmet T: Thrombin stimulates activation of the cerebral 5-lipoxygenase pathway during blood-brain cell contact. J Cereb Blood Flow Metab 16, 737-745 (1996)
100. Kuhn H, Belkner J, Wiesner R and Brash AR: Oxygenation of biological membranes by the pure reticulocyte lipoxygenase. J Biol Chem 265, 18351-18361 (1990)
101. Maccarrone M, Navarra M, Corasaniti MT, Nistico G and Finazzi Agro A: Cytotoxic effect of HIV-1 coat glycoprotein gp120 on human neuroblastoma CHP100 cells involves activation of the arachidonate cascade. Biochem J 333, 45-49 (1998)
102. Baskaya MK, Hu Y, Donaldson D, Maley M, Rao AM, Prasad MR and Dempsey RJ: Protective effect of the 5-lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia. J Neurosurg 85, 112-116 (1996)
103. Girard J, Panizzon K and Wallis RA: Azelastine protects against CA1 traumatic neuronal injury in the hippocampal slice. Eur J Pharmacol 300, 43-49 (1996)
104. Wallis RA and Panizzon KL: Protection from hypoxic and N-methyl-D-aspartate injury with azelastine, a leukotriene inhibitor. Eur J Pharmacol 238, 165-171 (1993)
105. Crooks SW and Stockley RA: Leukotriene B4. Int J Biochem Cell Biol 30, 173-178 (1998)
106. Yokomizo T, Izumi T, Chang K, Takuwa Y and Shimizu T: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387, 620-624 (1997)
107. Provost P, Samuelsson B and Radmark O: Interaction of 5-lipoxygenase with cellular proteins. Proc Natl Acad Sci USA 96, 1881-1885 (1999)
108. Kinouchi T, Ono Y, Sorimachi H, Ishiura S and Suzuki K: Arachidonate metabolites affect the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein. Biochem Biophys Res Commun 209, 841-849 (1995)
109. Kolasa T, Brooks CD, Rodriques KE, Summers JB, Dellaria JF, Hulkower KI, Bouska J, Bell RL and Carter GW: Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. J Med Chem 40, 819-824 (1997)
110. Muller-Peddinghaus R: Pharmacological aspects of 5-lipoxygenase inhibition. Adv Exp Med Biol 447, 117-121 (1999)
111. Kirchner T, Aparicio B, Argentieri DC, Lau CY and Ritchie DM: Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 56, 417-423 (1997)